

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.

These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.

Some data have been adjusted to facilitate estimates of standard indicators across countries.

Details of the process for searching, grading and including data, along with their interpretation, are detailed in:

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

For more information on the Reference Group, please go to: www.IDURefGroup.Com

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
1. Needle and syringe programs (NSPs)	5
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
2. Opioid substitution programs (OST)	10
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

Section	Page
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
3. Other Drug Treatment (ODT)	24
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
4. HIV testing and counselling (T&C)	41
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

Section	Page
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
5. Anti-retro-viral (ARV) treatment	45
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
6. Condoms	48
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

Kyrgyzstan (Central Asia)

Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	0.55	0.74	0.97
Year of IDU prevalence estimate	2006		
Reference for IDU prevalence estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	2.4	8	13.6
Year of HIV prevalence among IDU estimate	2005		
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age in 2008	3 512 464 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	19 000	26 000	34 000
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	456	2080	4624

1. Needle and syringe programs (NSPs)

NSP 1: Availability of NSPs

Are NSPs available?	Yes
Comments	
Most recent year of documentation	2008
Reference	See references for other NSP indicators
When were NSPs first introduced?	
Reference	
Are needles and syringes available for purchase from pharmacies?	Yes
Most recent year of documentation	2008
Reference	Interagency Youth Working Group (2008). Youth and injecting drug users. Youth Lens on reproductive health and HIV/AIDS. North Carolina, Interagency Youth Working Group. Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.

NSP 2: Number of NSP sites

Data reported	40 sites		
Year of reported data	2009		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	40		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	1.14	1.51	2.05

NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported	Needles and syringes available for purchase from pharmacies but number of sites not available		
Year of reported data	2008		
Reference	Interagency Youth Working Group (2008). Youth and injecting drug users. Youth Lens on reproductive health and HIV/AIDS. North Carolina, Interagency Youth Working Group. Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	2006		
General population 15-64 years of age at year of reported data	3 512 464 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	26 000	34 000
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data	(source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	NSP present but number not known		
Year of reported data	2009		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	NK	NK	NK

NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	NSP present but number not known		
Year of reported data	2009		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	NK	NK	NK

NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

Data reported	NSP present but number not known		
Year of reported data	2009		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU	Low	Mid	High
	NK	NK	NK

NSP: All documents reviewed

Aceijas, C., M. Hickman, et al. (2007). "Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia.[see comment]." *Addiction* 102(8): 1244-50.

AVERT. (2008). "HIV and AIDS in Russian Eastern Europe & Central Asia." Retrieved 30 November, 2008, from <http://www.avert.org/aids-russia.htm>

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Canadian HIV/AIDS Legal Network (2006). Prison needle exchange: Lessons from a comprehensive review of international evidence and

Country coordinating mechanism - Kyrgyzstan (2007). Proposal form - round 7. Bishkek: 131.

EHRN (2008). Overdose: A major cause of preventable death in Central and Eastern Europe and Central Asia. Recommendations and overview of the situation in Latvia, Kyrgyzstan, Romania, Russia and Tajikistan.

Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC.

Godinho, J., T. Novotny, et al. (2004). HIV/AIDS and Tuberculosis in Central Asia. Working Paper No. 20. The World Bank. Washington, DC.

Interagency Youth Working Group (2008). Youth and injecting drug users. Youth Lens on reproductive health and HIV/AIDS. North Carolina, Interagency Youth Working Group.

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

International Harm Reduction Development Program (2008). Harm reduction developments 2008. New York.

Jurgens, R. (2007). Interventions to address HIV in prisons: needle and syringe programmes and decontamination strategies. Geneva, World Health Organisation (WHO).

Jurgens, R. and G. Betteridge (2005). "Prisoners who inject drugs: public health and human rights imperatives." *Health & Human Rights* 8(2): 46-

Moller, L. F., B. J. van den Bergh, et al. (2008). "Drug use in prisons in Kyrgyzstan: a study about the effect of health promotion among prisoners." *International journal of prison health*. 4(3): 124-33.

Open Society Institute (2007). "News report shows benefit of Prison Needle Exchange." Retrieved 1st December, 2008, from http://www.soros.org/initiatives/health/focus/ihrd/news/prisonnep_20041027.

Prevention Committee (2005). Report on public policy for HIV prevention in Mainland France, Conseil national du sida.

The Macfarlane Burnet Institute for Medical Research & Public Health Ltd (2005). Policy and programming guide for HIV/AIDS prevention and care among injecting drug users. Melbourne, World Health Organisation: department of HIV/AIDS.

Todd, C. S., B. Nassiramanesh, et al. (2007). "Emerging HIV epidemics in Muslim countries: assessment of different cultural responses to harm reduction and implications for HIV control." *Current HIV/AIDS Reports* 4(4): 151-7.

UNAIDS (2008). Eastern Europe and Central Asia mapping prevention interventions in the CIS region.

United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Central Asia". Tehran.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".

World Health Organisation (WHO) (2005). Status paper on prisons, drugs, and harm reduction, World Health Organisation (WHO).

2. Opioid substitution treatment (OST)**OST 1: Availability of opioid substitution treatment (OST)**

Are any forms of agonist OST available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was agonist OST first available?	
Reference	

OST 2: Availability of methadone maintenance treatment (MMT)

Is MMT available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was MMT first available?	
Reference	

OST 3: Availability of buprenorphine maintenance treatment (BMT)

Is BMT available?	No
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was BMT first available?	
Reference	

OST 4: Availability of other forms of agonist OST

Are other forms of OST available?	
Comments	
Most recent year of documentation	
Reference	
When were other forms of OST first available?	
Reference	

OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	60 mg
Comments	
Year	2009
Reference	World Health Organisation (2009). Global health ATLAS data.
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	
Comments	
Year	
Reference	
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

OST 7: Total number of all sites providing OST

Data reported	14 OST sites 18 MMT sites 0 BMT site		
Year of reported data	2008 2009		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO. UNODC (2009). Status of OST provision and plans for 2010. UNODC (2009). Status of OST provision and plans for 2010.		
Adjustments	Figures taken as range		
Final/Adjusted data (to be used as indicator numerator)	14 - 18		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	0.40	0.60	0.92

OST 8: Number of sites providing MMT

Data reported	18 MMT sites		
Year of reported data	2009		
Reference	UNODC (2009). Status of OST provision and plans for 2010.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	18		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	0.51	0.68	0.92

OST 9: Number of sites providing BMT

Data reported	BMT not available		
Year of reported data	2009		
Reference	UNODC (2009). Status of OST provision and plans for 2010.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	0	0	0

OST 10: Number of sites providing other forms of agonist OST

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High

OST 11: Number of all clients in any OST at a single point in time

Data reported	730 - 735 clients in MMT 0 clients in BMT [No information on whether number of clients in OST at single point in time (i.e. Census date) or total number of clients receiving OST over a period of time]		
Year of reported data	2009 2008		
Reference	World Health Organisation (2009). Global health ATLAS data. International AIDS Society (2008). Opioid substitution therapy in selected countries of East European and Central Asia.		
Adjustments	Assumed enrolment at a census date 2009 data also available (See: UNODC (2009). Status of OST provision and plans for 2010.) but 2008 data taken in preference in accordance with the census date for this review.		
Final/Adjusted data (to be used as indicator numerator)	730 - 735		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs	Low	Mid	High
	2.09	2.76	3.77

OST 12: Number of all clients in MMT at a single point in time

Data reported	730 patients on MMT 735 clients in MMT [No information on whether number of clients in MMT at single point in time (i.e. Census date) or total number of clients receiving MMT over a period of time]		
Year of reported data	2009 2008		
Reference	World Health Organisation (2009). Global health ATLAS data. International AIDS Society (2008). Opioid substitution therapy in selected countries of East European and Central Asia.		
Adjustments	Assumed enrolment at a census date Figures taken as range		
Final/Adjusted data (to be used as indicator numerator)	730 - 735		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs	Low	Mid	High
	2.09	2.76	3.77

OST 13: Number of all clients in BMT at a single point in time

Data reported	BMT not available		
Year of reported data	2009		
Reference	See references for other OST indicators		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	0	0	0

OST 14: Number of all clients in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High

OST 15: Number of IDUs in any OST at a single point in time

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2008		
Reference	International AIDS Society (2008). Opioid substitution therapy in selected countries of East European and Central Asia.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 512 464 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	26 000	34 000
INDICATOR: Percentage of IDUs in OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST 16: Number of IDUs in MMT at a single point in time

Data reported	MMT available but number of IDUs not known		
Year of reported data	2008		
Reference	International AIDS Society (2008). Opioid substitution therapy in selected countries of East European and Central Asia.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 512 464 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	26 000	34 000
INDICATOR: Percentage of IDUs in MMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 17: Number of IDUs in BMT at a single point in time

Data reported	BMT not available		
Year of reported data	2009		
Reference	See references for other OST indicators		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	0	0	0

OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High

OST 19: Number of all clients receiving any OST in a 12 month period

Data reported	735 clients in MMT 0 clients in BMT [No information on whether number of clients in OST at single point in time (i.e. Census date) or total number of clients receiving OST over a period of time]		
Year of reported data	2008		
Reference	International AIDS Society (2008). Opioid substitution therapy in selected countries of East European and Central Asia.		
Adjustments	Assumed total number of clients enrolled in OST throughout 2008 2009 data also available (See: UNODC (2009). Status of OST provision and plans for 2010.) but 2008 data taken in preference in accordance with the census date for this review.		
Final/Adjusted data (to be used as indicator numerator)	735		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 512 464 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	26 000	34 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs	Low	Mid	High
	2.16	2.83	3.87

OST 20: Number of all clients receiving MMT in a 12 month period

Data reported	735 clients in MMT [No information on whether number of clients in MMT at single point in time (i.e. Census date) or total number of clients receiving MMT over a period of time]		
Year of reported data	2008		
Reference	International AIDS Society (2008). Opioid substitution therapy in selected countries of East European and Central Asia.		
Adjustments	Assumed total number of clients enrolled in MMT throughout 2008		
Final/Adjusted data (to be used as indicator numerator)	735		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 512 464 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	26 000	34 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs	Low	Mid	High
	2.16	2.83	3.87

OST 21: Number of all clients receiving BMT in a 12 month period

Data reported	BMT not available		
Year of reported data	2009		
Reference	See references for other OST indicators		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	0	0	0

OST 22: Number of all clients receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High

OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2008		
Reference	International AIDS Society (2008). Opioid substitution therapy in selected countries of East European and Central Asia.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 512 464 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	26 000	34 000
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	MMT available but number of IDUs not known		
Year of reported data	2008		
Reference	International AIDS Society (2008). Opioid substitution therapy in selected countries of East European and Central Asia.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 512 464 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	26 000	34 000
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 25: Number of IDUs receiving BMT in a 12 month period

Data reported	BMT not available		
Year of reported data	2009		
Reference	See references for other OST indicators		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	0	0	0

OST 26: Number of IDUs receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High

OST: All documents reviewed

AVERT. (2008). "HIV and AIDS in Russian Eastern Europe & Central Asia." Retrieved 30 November, 2008, from <http://www.avert.org/aids-russia.htm>

Country coordinating mechanism - Kyrgyzstan (2007). Proposal form - round 7. Bishkek: 131.

Country coordinating mechanism - Kyrgyzstan (2008). Increasing universal access to prevention, detection, treatment, care and support for key population groups in the Kyrgyz Republic. Bishkek: 18.

Esenamanova, A. (2008). "Fighting AIDS in Kyrgyzstan." from http://www.theglobalfund.org/en/savinglives/kyrgyzstan/hiv1/transcript_en/ (accessed 14:05 30/3/2009)

Eurasian Harm Reduction Network, ECCB, et al. (2008). Substitution therapy in 9 countries in Eastern Europe and Central Asia.

Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC.

International AIDS Society (2008). Expanding access to opioid substitution therapy for injecting drug users in Eastern Europe and Central Asia. IAS Yalta Scientific Leadership Summit.

International AIDS Society (2008). Opioid substitution therapy in selected countries of East European and Central Asia.

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

International Harm Reduction Development Program (2008). Harm reduction developments 2008. New York.

UNAIDS (2008). Eastern Europe and Central Asia mapping prevention interventions in the CIS region.

United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Central Asia". Tehran.

UNODC (2008). Milestones: October, 2008 Regional Office for Central Asia. UNODC Regional Office for Central Asia.

UNODC (2009). Status of OST provision and plans for 2010.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".

3. Other drug treatment (ODT)**ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

Is detoxification available?	Yes		
Number of sites - data reported	Detoxification available but number not known		
Year of reported data	2005		
Reference	<p>Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC.</p> <p>Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	3 283 255 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	18 000	24 500	32 000
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 1.2: Number of IDUs receiving detoxification

Data reported	Detoxification available but number not known		
Year of reported data	2005		
Reference	<p>Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC.</p> <p>Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".</p>		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	3 283 255 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	18 000	24 500	32 000
INDICATOR: Percentage of IDUs in detoxification in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in detoxification at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

Data reported	Detoxification available but number not known		
Year of reported data	2005		
Reference	<p>Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC.</p> <p>Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".</p>		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	3 283 255 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	18 000	24 500	32 000
INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 2 - Residential rehabilitation

ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?	Yes		
Number of sites - data reported	Residential rehabilitation present but number not known		
Year of reported data	2005		
Reference	Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC. Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 283 255 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	18 000	24 500	32 000
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 2.2: Number of IDUs in residential rehabilitation

Data reported	Residential rehabilitation present but number not known		
Year of reported data	2005		
Reference	<p>Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC.</p> <p>Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".</p>		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	3 283 255 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	18 000	24 500	32 000
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 2.3: Number of all clients in residential rehabilitation

Data reported	Residential rehabilitation present but number not known		
Year of reported data	2005		
Reference	<p>Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC.</p> <p>Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".</p>		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	3 283 255 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	18 000	24 500	32 000
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?	Yes		
Number of sites - data reported	Counselling, peer based group support and cognitive behaviour therapy available for MMT clients		
Year of reported data	2005		
Reference	Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC. Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 283 255 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	18 000	24 500	32 000
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2005		
Reference	<p>Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC.</p> <p>Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".</p>		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	3 283 255 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	18 000	24 500	32 000
INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2005		
Reference	<p>Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC.</p> <p>Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".</p>		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	3 283 255 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	18 000	24 500	32 000
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 4 - Peer-based support groups

ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	4 NA meetings per week		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	4		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 512 464 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	26 000	34 000
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	0.12	0.15	0.21

ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 512 464 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	26 000	34 000
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 4.3: Number of all clients in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 512 464 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	26 000	34 000
INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs	Low	Mid	High
	NK	null	null

ODT 5 - Drug treatment (treatment type not specified)

ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High

ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High

ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High

ODT 6 - Drug treatment in prisons

ODT 6.1: Number of prison drug treatment sites

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High

ODT: All documents reviewed

Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC.

Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".

4. HIV testing and counselling (T&C)

T&C 1: Availability of HIV T&C

Is T&C available?	Yes
Most recent year of data	2008
Reference	See references for other VCT indicators

T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported	8 sites		
Year of reported data	2007		
Reference	Country coordinating mechanism - Kyrgyzstan (2008). Increasing universal access to prevention, detection, treatment, care and support for key population groups in the Kyrgyz Republic. Bishkek: 18		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	8		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 434 775 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	25 500	33 500
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High
	0.24	0.31	0.42

T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported	VCT available but number not known		
Year of reported data	2007		
Reference	Country coordinating mechanism - Kyrgyzstan (2008). Increasing universal access to prevention, detection, treatment, care and support for key population groups in the Kyrgyz Republic. Bishkek: 18		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 434 775 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	25 500	33 500
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High

T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	2008 2007
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO. UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.
Data reported for both male and female IDUs	32% IDUs received an HIV test in the last 12 months and know their results 34% IDUs received an HIV test in the last 12 months and know their results
Adjustments	Assumed data from 2008 -
Final/Adjusted data	32% - 34%
Data reported for male IDUs	32% male IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	32.00%
Data reported for female IDUs	43% female IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	43.00%

T&C: All documents reviewed

Country coordinating mechanism - Kyrgyzstan (2008). Increasing universal access to prevention, detection, treatment, care and support for key population groups in the Kyrgyz Republic. Bishkek: 18.

UNAIDS (2008). Eastern Europe and Central Asia mapping prevention interventions in the CIS region.

UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".

5. Anti-retro-viral (ARV) treatment**ARV 1: Number of sites providing ARV treatment**

Data reported	66 sites		
Year of reported data	2009		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	66		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 587 513 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 500	26 500	35 000
HIV among IDU prevalence estimate (%)	Low	Mid	High
	2.40	8	13.60
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)	Low	Mid	High
	468	2120	4760
INDICATOR: Number of ARV treatment sites per 1000 IDUs	Low	Mid	High
	1.89	2.49	3.38
INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV	Low	Mid	High
	13.87	31.13	141.03

ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported	12 IDU on HAART also receiving OST IDUs receiving HAART and OST represent 32% of all IDUs on HAART		
Year of reported data	2006		
Reference	WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	38		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 357 607 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	18 500	25 000	32 500
HIV among IDU prevalence estimate (%)	Low	Mid	High
	2.40	8	13.60
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	444	2000	4420
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High
	0.86	1.90	8.56

ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	
Year of reported data	
Reference	

ARV: All documents reviewed

Aceijas, C., E. Oppenheimer, et al. (2006). "Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5")." *Addiction* 101(9): 1246-53.

Country coordinating mechanism - Kyrgyzstan (2007). Proposal form - round 7. Bishkek: 131.

Country coordinating mechanism - Kyrgyzstan (2008). Increasing universal access to prevention, detection, treatment, care and support for key population groups in the Kyrgyz Republic. Bishkek: 18.

European AIDS Treatment Group (2008). Antiretroviral treatment for injecting drug users in Central and Eastern Europe.

Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC.

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

Wolfe, D. (2005). Pointing the way: harm reduction in kyrgyz republic, Harm Reduction Association of Kyrgyzstan "Partners' network".

6. Condoms

Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	Yes
Comments	
Year	2007
Reference	Nasritdinov, N. Z. and M. A (2007). "Friendly Pharmacy Project": A innovative project in Kyrgyzstan, C3-5. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland, International Harm Reduction Association (IHRA),.

Condoms 2: Number of sites distributing condoms to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2007		
Reference	Nasritdinov, N. Z. and M. A (2007). "Friendly Pharmacy Project": A innovative project in Kyrgyzstan, C3-5. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland, International Harm Reduction Association (IHRA),.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 434 775 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	25 500	33 500
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	NK	NK	NK

Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High

Condoms 4: Number of condoms distributed to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2007		
Reference	Nasritdinov, N. Z. and M. A (2007). "Friendly Pharmacy Project": A innovative project in Kyrgyzstan, C3-5. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland, International Harm Reduction Association (IHRA),.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.55	0.74	0.97
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 434 775 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	19 000	25 500	33 500
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	NK	NK	NK

Condoms: All documents reviewed

Country coordinating mechanism - Kyrgyzstan (2008). Increasing universal access to prevention, detection, treatment, care and support for key population groups in the Kyrgyz Republic. Bishkek: 18.

Godinho, J., A. Renton, et al. (2005). Reversing the Tide: Priorities for HIV/AIDS Prevention in Central Asia. Working Paper No. 54. World Bank. Washington, DC.

Nasritdinov, N. Z. and M. A (2007). "Friendly Pharmacy Project": A innovative project in Kyrgyzstan, C3-5. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland, International Harm Reduction Association (IHRA),.